Back to search results

A Study of ABBV-295 for Overweight or Obesity in Healthy Japanese Adults

This study is testing a new medication called ABBV-295, given as shots under the skin, in healthy Japanese adults who are overweight or have obesity. Researchers want to see if ABBV-295 is safe and how well your body handles it (tolerability). They will also study how the body processes the medication (pharmacokinetics). You can join if you are between 18 and 65 years old and are of full Japanese parentage. The main goal is to track any side effects you might experience over about 138 days. The study is currently recruiting 24 participants, but its status is unclear.

Study design
This interventional study plans to enroll 24 healthy adult Japanese participants. It will compare ABBV-295 to a placebo (an inactive substance).
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for up to approximately 138 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07514260

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

Active, Not Recruiting
PHASE1Ages 18–65InterventionalBasic science
AbbVie
~24 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:ABBV-295Placebo for ABBV-295

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with Adverse Events (AEs)
Measured over Up to approximately 138 days

Conditions

Healthy Volunteer

Explore related trials

Healthy Volunteer

Where it's being run

1 sites across 1 states
California1

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Japanese participant must be first-or second-generation Japanese of full Japanese parentage.
BMI is ≥ 23.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

Exclusion

Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
Participant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-1, (GLP-1) agonists, Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.

What this trial measures

  • Number of Participants with Adverse Events (AEs)Up to approximately 138 days

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.